NCT05823701View on ClinicalTrials.gov

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Chidamide

20 mg (4 capsules), d1, d4, d8, d11 orally per cycle

DRUG

Azacitidine

100mg d1- d5 subcutaneous injection per cycle

BIOLOGICAL

obinutuzumab

1000mg d4 intravenous infusion per cycle

DRUG

Liposomal mitoxantrone

20mg/m2 d5 intravenous infusion per cycle

Trial Locations (1)

215006

RECRUITING

the First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER